Bupropion

Generic Name: Bupropion

Brand Names: Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈ClNO

CAS Number: 34911-55-2

Unique Ingredient Identifier: 01ZG3TPX31

Background: Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication: Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)

Associated Therapies: Smoking, Cessation, Weight Loss

Clinical Trials

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

Phase 1

Completed

Conditions: Smoking
Nicotine Dependence

Interventions: Drug: Naltrexone
Drug: Bupropion

First Posted Date: 2005-08-11

Last Posted Date: 2020-12-03

Lead Sponsor: Yale University

Target Recruit Count: 40

Registration Number: NCT00129246

Locations: 🇺🇸
Yale University School of Medicine Substance Abuse Treatment Unit, New Haven, Connecticut, United States

ISTAPS: A Stepped Primary Care Smoking Cessation Intervention

Not Applicable

Conditions: Smoking Cessation

First Posted Date: 2005-08-02

Last Posted Date: 2009-09-30

Lead Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Target Recruit Count: 3012

Registration Number: NCT00125905

Locations: 🇪🇸
Jordi Gol i Gurina Foundation-Primary Care Research Institute, Barcelona, Spain

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

Phase 3

Completed

Conditions: Major Depressive Disorder
Depression
Unipolar Depression

Interventions: Drug: Wellbutrin
Drug: Placebo

First Posted Date: 2005-08-02

Last Posted Date: 2014-08-06

Lead Sponsor: Mclean Hospital

Target Recruit Count: 32

Registration Number: NCT00125957

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

Phase 2

Completed

Conditions: Schizophrenia
Tobacco Use Cessation
Tobacco Use Disorder

Interventions: Drug: Bupropion
Drug: nicotine transdermal patch

First Posted Date: 2005-07-28

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 59

Registration Number: NCT00124683

Brain Reaction to Treatment of Nicotine Dependence

Phase 1

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Zyban

First Posted Date: 2005-04-15

Last Posted Date: 2013-04-09

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 104

Registration Number: NCT00108173

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, West LA, West Los Angeles, California, United States

Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression

Phase 4

Conditions: Depression

Interventions: Drug: Bupropion

First Posted Date: 2005-03-22

Last Posted Date: 2013-08-30

Lead Sponsor: Uma Rao

Target Recruit Count: 130

Registration Number: NCT00106197

Locations: 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States

Framing Messages for Smoking Cessation With Bupropion - 6

Not Applicable

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Bupropion
Behavioral: Smoking Abstinence Program

First Posted Date: 2005-03-02

Last Posted Date: 2013-08-09

Lead Sponsor: Yale University

Target Recruit Count: 252

Registration Number: NCT00104598

Locations: 🇺🇸
Substance Abuse Treatment Unit, New Haven, Connecticut, United States

Comparing Smoking Treatment Programs for Lighter Smokers - 1

Phase 2

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: bupropion
Drug: nicotine transdermal system
Behavioral: Medication Management
Behavioral: Mayo Counseling
Drug: placebo bupropion
Drug: placebo patch

First Posted Date: 2004-07-07

Last Posted Date: 2019-08-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 260

Registration Number: NCT00086411

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Treatment of Adolescent Suicide Attempters (TASA)

Phase 2

Completed

Conditions: Suicide, Attempted
Depression

First Posted Date: 2004-03-26

Last Posted Date: 2020-06-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 120

Registration Number: NCT00080158

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸
New York University Child Study Center, New York, New York, United States

and more 3 locations

Bupropion for the Treatment of Methamphetamine Dependence - 1

Phase 2

Completed

Conditions: Amphetamine-Related Disorders

First Posted Date: 2003-09-24

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 150

Registration Number: NCT00069251

Locations: 🇺🇸
Matrix Institute on Addictions, Costa Mesa, California, United States
🇺🇸
South Bay Treatment Center, San Diego, California, United States
🇺🇸
Pacific Addiction Research Center, Honolulu, Hawaii, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy